The authors further supported this hypothesis by flow cytometry, demonstrating that anti-PD-1 treatment in HLA-A02+ patients with melanoma led to greater expansion of melanocyte antigen MART-1-specific CD8+ T cells in responders than in nonresponders. Here, CD8A is linked to melanoma.